Skip to main content
. Author manuscript; available in PMC: 2024 Jul 7.
Published in final edited form as: Eur J Cancer. 2024 Jan 11;199:113530. doi: 10.1016/j.ejca.2024.113530

Table 2.

Summary of all-cause AEs.

31-trial pooled safety dataset Label safety dataset
N = 8937 N = 2799
AEs of any cause 8630 (96.6) 2727 (97.4)
 Grade 3–5 AEs 4525 (50.6) 1273 (45.5)
 Serious AEs 3513 (39.3) 1042 (37.2)
 Led to discontinuation 1135 (12.7) 334 (11.9)
 Led to death 527 (5.9) 110 (3.9)
Any AE in ≥ 10% of patients in either dataset
 Fatigue 2654 (29.7) 1044 (37.3)
 Nausea 1827 (20.4) 685 (24.5)
 Decreased appetite 1812 (20.3) 630 (22.5)
 Diarrhea 1773 (19.8) 625 (22.3)
 Constipation 1585 (17.7) 498 (17.8)
 Cough 1570 (17.6) 615 (22.0)
 Pruritus 1522 (17.0) 580 (20.7)
 Arthralgia 1480 (16.6) 636 (22.7)
 Anemia 1458 (16.3) 347 (12.4)
 Dyspnea 1332 (14.9) 534 (19.1)
 Rash 1212 (13.6) 508 (18.1)
 Vomiting 1198 (13.4) 387 (13.8)
 Pyrexia 1182 (13.2) 357 (12.8)
 Asthenia 1059 (11.8) 362 (12.9)
 Back pain 1019 (11.4) 344 (12.3)
 Hypothyroidism 935 (10.5) 236 (8.4)
 Abdominal pain 923 (10.3) 274 (9.8)
 Headache 885 (9.9) 400 (14.3)

Data are n (%).

AE, adverse event.